Due to the specific binding to tumor PD‐L1, ZPD‐L1 endows this nanoplatform with efficient tumor targeting and meanwhile reduces immune suppression of T cells by achieving PD‐1/PD‐L1 blockade, intensifying RT‐induced immunologic cell death. Here, CD274 is linked to neoplasm.